• 1
    Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 17411751.
  • 2
    Rentenaar RJ, Gamadia LE, Van Der Hoek N et al. Development of virus-specific CD4(+) T cells during primary cytomegalovirus infection. J Clin Invest 2000; 105: 541548.
  • 3
    Rowshani AT, Bemelman FJ, Van Leeuwen EMM, Van Lier RAW, Ten Berge IJM. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2005; 79: 381386.
  • 4
    Gamadia LE, Remmerswaal EBM, Weel JF, Bemelman F, Van Lier RAW, Ten Berge IJM. Primary immune responses to human CMV: A critical role for IFN-g-producing CD4+ T cells in protection against CMV disease. Blood 2003; 101: 26862692.
  • 5
    Radha R, Jordan S, Puliyanda D et al. Cellular immune responses to cytomegalovirus in renal transplant recipients. Am J Transplant 2005; 5: 110117.
  • 6
    Shlobin OA, West EE, Lechtzin N et al. Persistent cytomegalovirus-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J Immunol 2006; 176: 26252634.
  • 7
    Westall G, Kotsimbos T, Brooks A. CMV-specific CD8 T-cell dynamics in the blood and the lung allograft reflect viral reactivation following lung transplantation. Am J Transplant 2006; 6: 577584.
  • 8
    Sester U, Gartner BC, Wilkens H et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005; 5: 14831489.
  • 9
    Quinnan GVJr, Kirmani N, Rook AH et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982; 307: 713.
  • 10
    Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78: 13731380.
  • 11
    Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 19711979.
  • 12
    Waldrop SL, Pitcher CJ, Peterson DM, Maino VC, Picker LJ. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: Evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest 1997; 99: 17391750.
  • 13
    Cwinarski K, Ainsworth J, Cobbold M et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001; 97: 12321240.
  • 14
    Gratama JW, Van Esser JWJ, Lamers CHJ et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001; 98: 13581364.
  • 15
    Hebart H, Daginik S, Stevanovic S et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-γ-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002; 99: 38303837.
  • 16
    Kern F, Faulhaber N, Frommel C et al. Analysis of CD8+ T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 2000; 30: 16761682.
  • 17
    Sester M, Sester U, Gärtner B, Girndt M, Meyerhans A, Kohler H. Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol 2002; 13: 25772584.
  • 18
    Lozza L, Lilleri D, Percivalle E et al. Simultaneous quantification of human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells. Eur J Immunol 2005; 35: 17951804.
  • 19
    Ljungman P, Griffiths P, Paya C. Definition of HCMV infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 10941097.
  • 20
    Gerna G, Revello MG, Percivalle E, Morini F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992; 30: 12321237.
  • 21
    Gerna G, Percivalle E, Torsellini M, Revello MG. Standardization of the human cytomegalovirus antigenemia assay by means of in vitro generated pp65-positive peripheral blood polymorphonuclear leukocytes. J Clin Microbiol 1998; 36: 35853589.
  • 22
    Gerna G, Baldanti F, Lilleri D et al. Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: A prospective, randomized, controlled, open-label trial. Transplantation 2003; 75: 10121019.
  • 23
    Gerna G, Vitulo P, Rovida F et al. Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J Med Virol 2006; 78: 408416.
  • 24
    Lilleri D, Baldanti F, Gatti M et al. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy of human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients. J Med Virol 2004; 73: 412418.
  • 25
    Gerna G, Revello MG, Percivalle E, Zavattoni M, Parea M, Battaglia M. Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins. J Clin Microbiol 1990; 28: 26812688.
  • 26
    Gerna G, Revello MG, Percivalle E, Torsellini M. 6-h microneutralization assay for human cytomegalovirus antibody by using monoclonal antibodies. Serodiagn Immunother Infect Dis 1990; 4: 243247.
  • 27
    Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 11091118.
  • 28
    Gerna G, Percivalle E, Lilleri D et al. Dendritic cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol 2005; 86: 275284.
  • 29
    Grossi P, Minoli L, Percivalle E, Irish W, Viganò M, Gerna G. Clinical and virological monitoring of human CMV infection in 294 heart transplant recipients. Transplantation 1995; 59: 847851.
  • 30
    Gerna G, Zavattoni M, Baldanti F et al. Human cytomegalovirus (HCMV) leukoDNAemia correlates more closely with clinical symptoms than antigenemia and viremia in heart and heart-lung transplant recipients with primary HCMV infection. Transplantation 1998; 65: 13781385.
  • 31
    Hassan-Walker AF, Vargas Cuero AL, Mattes FM et al. CD8+ cytotoxic lymphocyte response against cytomegalovirus after liver transplantation: Correlation with time from transplant to receipt of tacrolimus. J Infect Dis 2001; 183: 835843.
  • 32
    Engstrand M, Tournay C, Peyrat MA et al. Characterization of CMV pp65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants. Transplantation 2000; 69: 22432250.
  • 33
    Sester M, Sester U, Gartner B et al. Levels of virus-specific CD4+ T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001; 71: 12871294.
  • 34
    Gamadia LE, Rentenaar RJ, Baars PA et al. Differentiation of cytomegalovirus-specific CD8+ T cells in healthy and immunosuppressed virus carriers. Blood 2001; 98: 754761.